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Abstract
Prenatal inflammation is considered an important factor contributing to preterm birth and neonatal mortality and
morbidity. The impact of prenatal inflammation on fetal bioenergetic status and the correlation of specific metabolites to
inflammatory-induced developmental brain injury are unknown. We used a global metabolomics approach to examine
plasma metabolites differentially regulated by intrauterine inflammation. Preterm-equivalent sheep fetuses were
randomized to i.v. bolus infusion of either saline-vehicle or LPS. Blood samples were collected at baseline 2 h, 6 h and
daily up to 10 days for metabolite quantification. Animals were killed at 10 days after LPS injection, and brain injury was
assessed by histopathology. We detected both acute and delayed effects of LPS on fetal metabolism, with a long-term
down-regulation of fetal energy metabolism. Within the first 3 days after LPS, 121 metabolites were up-regulated or down-
regulated. A transient phase (4–6 days), in which metabolite levels recovered to baseline, was followed by a second phase
marked by an opposing down-regulation of energy metabolites, increased pO2 and increased markers of inflammation and
ADMA. The characteristics of the metabolite response to LPS in these two phases, defined as 2 h to 2 days and at 6–9 days,
respectively, were strongly correlated with white and grey matter volumes at 10 days recovery. Based on these results we
propose a novel concept of inflammatory-induced hibernation of the fetus. Inflammatory priming of fetal metabolism
correlated with measures of brain injury, suggesting potential for future biomarker research and the identification of
therapeutic targets.
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Introduction
The annual rate of neonatal mortality is approximately four
million neonatal deaths worldwide, with the majority resulting
from asphyxia (23%), infections (36%), and prematurity (28%) [1].
Preterm birth (delivery before 37 completed weeks of gestation) is
the single major risk factor for perinatal mortality and morbidity
in both high- and low-income countries. The global annual
prematurity rate is 9.6%, representing 12.9 million births [1].
Surviving preterm infants also have high rates of long-term health
complications including cerebral palsy, visual or hearing impair-
ment, respiratory illnesses, learning difficulties and behavioral
disorders [2].
Prenatal infection or inflammation is a major cause of preterm
birth, and can also contribute to poor postnatal growth,
pulmonary and neurological morbidity, and mortality [3–5]. A
causative role for infection per se in white matter injury is supported
from animal experiments [6]. Further, we recently demonstrated
that fetal infection is associated with delayed impairment of both
white matter and cortical development [7].
In adult septic patients, sepsis has been shown to be associated
with mitochondrial dysfunction in muscle [8]. This condition is
considered an important factor regulating multisystem organ
failure, morbidity and mortality in septic patients. However,
despite the strong support for a key role of prenatal inflammation
in neonatal morbidity, the impact of prenatal inflammation on
fetal metabolism and bioenergetic failure is unknown. Further-
more, no specific metabolites have previously been shown to
correlate with inflammatory-induced developmental brain injury.
Metabolomics can bridge this information gap by elucidating
functional information, since metabolite differences in biological
fluids and tissues provide the closest link to various phenotypic
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the largest possible number of metabolites from relevant or
potentially impacted metabolic pathways, and is a promising
approach for the clinical investigation of prenatal inflammation. In
recent years, electrospray ionization (ESI) tandem mass spectrom-
etry (MS/MS), often applied in concert with an initial chroma-
tography purification/separation step, has been used in a number
of clinical metabolomic studies [10,11]. Generally, metabolomics
can be performed in a non-targeted (or ‘‘open’’ profiling) mode
using all the information from the spectrometer providing an
holistic view of the metabolome with minimal chemical bias, or in
so-called ‘‘targeted’’ mode, which relies on analytical protocols
optimized to measure specific groups/classes of compounds [12].
Quantitative targeted metabolomics using multiplexed tandem
mass spectrometry has matured to the point where it can now be
applied in a high-throughput manner [13] and such a targeted
approach was applied to this study.
The aim of this study was to examine the effect of inflammation
on the plasma metabolome in a model of preterm brain injury in
fetal sheep in order to: a) obtain novel descriptive information on
dynamic metabolic changes after LPS-induced inflammation, b)
investigate the predictive ability of the blood metabolome for brain
injury, which could theoretically be useful for development of
clinical predictive markers, and c) form the basis for potential
individualized therapies in preterm fetuses/babies in the future.
We examined the effect of lipopolysaccharide (LPS) exposure on
metabolism in 0.7 gestation fetal sheep, an age equivalent to 28–32
weeks gestation in humans and prior to the onset of cortical
myelination [14,15]. Our data demonstrate that inflammation
causes hibernation of fetal metabolism, and that the metabolite
response to LPS was strongly associated with cerebral white and
grey matter volumes at post mortem. Since metabolic pathways
are largely conserved across species and are therefore species-
independent, these metabolic fingerprints may translate as
potential biomarkers in the clinical setting.
Results
Impact of LPS exposure on vital parameters and arterial
blood gas analyses
The two cohorts had comparable blood gas readings at baseline
(p.0.2, Table 1), and no differences in bodyweight, gestational
age at LPS injection and post mortem fetal weight (Table 1).
Partial pressure of oxygen (pO2) and lactate concentration over the
course of the experiment are shown in Figure 1. For both
parameters, the main time and treatment effects and their
interaction were significant. Within the first 6 hours post injection,
LPS exposure caused an initial fall in pO2 and pH (Figure S1),
while lactate was increased 5–fold, compared to the controls.
These parameters largely resolved to control group levels by 1 day
recovery. In LPS treated animals, lactate was lower from days 8–
10 (q,0.05, Figure 1), while pO2 was elevated from days 5–9
(q,0.05, Figure 1), when compared to the sham group. Mean
arterial blood pressure (MABP) was not significantly different
between the groups at any time point [7].
Acute effects of intrauterine LPS exposure on fetal
metabolism
The impact of fetal LPS exposure on the plasma metabolome
was first assessed independently in the control cohort (n=7).
However, there were no common regulation patterns, and only
very few metabolites exhibited significant trends over the entire
experimental course. For example, arachidonic acid, PC aa C36:6,
PC ae C36:4, desmosterol and spermidine were the most
pronounced down-regulated metabolites over the 10 days recovery
(data not shown, FDR,0.01). By contrast, in the LPS group
(n=9), 113 out of 168 metabolites were significantly regulated
within the first 3 days (FDR,0.01). Figure S2 shows histograms of
the 168 raw p values obtained by time course modelling in the
LPS-treated and sham-operated animal cohorts. The patterns of
the altered phosphatidylcholines (56 compounds) and the
remaining metabolites (57 compounds) are shown in Figure S3
and Figure 2, respectively. Oxysterols, energy metabolism
intermediates and other relevant metabolites (Figure 2, left) have
been extracted from the rest of the metabolites (Figure 2, right) for
ease of interpretation. Clusters comprised a mixture of up- and
down-regulated metabolites, with the most extreme variation
attaining a more than a 10-fold change in measured plasma
concentration. Within the first 3 days, LPS exposure caused a
significant increase of the Krebs cycle intermediates, as well as
alanine and lactate, and a subsequent slight decrease in hexoses
(upper panel, Figure 2, left). Similarly 24-hydroxycholesterol
(24OHC) and 25-hydroxycholesterol (25OHC), 12S-HETE and
spermidine (lower panel) increased after LPS, peaking at 6 hours.
Polyamines, sphingomyelins, amino acids and acylcarnitines also
showed specific and distinct patterns after LPS exposure (Figure 2).
Delayed effects of LPS on plasma metabolome
We also tested the effects of LPS exposure on plasma
metabolites over 3–10 days recovery from LPS. The interaction
term denoting differences in concentration between treatment and
sampling time identified several metabolites of different classes.
Figure 3 (upper left panel) summarizes the number of metabolites
that differed between the LPS and control group on at least one
time point between days 3–10 in each class at various FDR (solid
lines). For example, three energy metabolism intermediates, 10
amino acids, four biogenic amines, two oxysterols, 10 PC’s and
one prostanoid differed significantly at FDR,0.001. The fold
changes of metabolites altered by LPS treatment at day 4 to day 10
is shown in Figure 3 (upper right and lower panel). In LPS exposed
animals, a-ketoglutarate, lactate and C5:1 were decreased by up to
50%, while hexose and C18:1-OH concentration were increased
by up to 80%, compared to the sham animals. The polyamines
ADMA, SDMA, the sum of ADMA and SDMA, 3-hydroxyky-
nurenine, kynurenine and spermidine as well as several amino
Table 1. Description of the cohort.
Sham (n=7) LPS (n=9) p-value
pH 7.39 (0.0331) 7.38 (0.029) 0.44
PO2 [mmHg] 22.7 (1.47) 23.8 (3.63) 0.41
sO2 56.2 (6.41) 59.6 (9.52) 0.40
Glucose [mmol/L] 0.771 (0.138) 0.844 (0.142) 0.32
Lactate [mmol/L] 1.2 (0.283) 1.06 (0.324) 0.36
cBase.Ecf [mmol/L] 21.29 (2.19) 21.28 (1.82) 0.99
SBC [mmol/L] 22.7 (1.83) 22.8 (1.47) 0.92
Grey matter volume [cm3] 2.79 (0.201) 2.35 (0.284) 0.0037
White matter volume [cm3] 1.47 (0.185) 1.19 (0.121) 0.011
Total brain weight [g] 24.8 (3.65) 22.7 (1.76) 0.20
Fetus weight [g] 1440 (285) 1470 (291) 0.82
Blood gas parameters are measured at baseline and histopathology findings
and fetus and brain weights at sacrifice. Statistics given as mean (standard
deviation) and p values computed by two sided Welch t-test.
doi:10.1371/journal.pone.0029503.t001
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group compared to the control group, whereas 25OHC was
decreased.
Correlation of plasma metabolites with brain injury
We recently demonstrated in this cohort that fetal LPS exposure
causes delayed impairment of both WM and cortical development
[7]. Here, we examined correlations of metabolite concentrations
with cortical gray (GM) and white matter (WM) volumes at post
mortem, as surrogate measures of brain injury. Multivariate
analysis using partial least squares regression revealed significant
associations (cross validated r=0.5020.77, Figure S4) between
cortical WM and GM volumes and metabolites levels at 6 h, and
1, 2, 6–9 days, but not at any other time points. We therefore
focused on metabolite correlations over an acute phase (6 h–2 d)
and a delayed phase (6–9 d). For both periods, we tested the time
of sampling and WM and cortical GM volumes as the main effects,
as well as their interactions. Density histograms of the raw p values
obtained for the correlation analyses of metabolites with (a) GM
and (b) WM volumes in the acute (6–48 h) and late phases (6–9 d)
are shown in Figure S5.
Metabolites that exhibited a significant association in at least
one sampling window/covariate combination are presented in the
form of a heat map of their original correlations to WM/GM
(FDR,0.1, Figure 4 and Figure S6 for phosphatidylcholines). In
the acute period (6 h–2 d), the associations between metabolites
Figure 1. Blood gas parameters. Lactate concentrations (A) and partial pressure of oxygen (B) over the whole course of the experiment. Mean
and 95% confidence intervals are given for the LPS (thick line) and the control (dashed line) groups (n=7 (control)/9 (LPS) +qv0.2; *, qv0.05;
**, qv0.001).
doi:10.1371/journal.pone.0029503.g001
Figure 2. Metabolite response to LPS in the acute phase. Cluster analysis of the time courses for the metabolites altered in the LPS cohort
within the first 3 days. Left: display of the time courses for 3 groups of metabolites altered in the LPS cohort within the first 3 days. Middle:
dendrogram from the hierachical clustering (HCA), based on the absolute value of the correlation between coefficients of the linear model. Right:
explicit display of each metabolite time course for each cluster identified by HCA. The average time course is plotted as a dashed line.
doi:10.1371/journal.pone.0029503.g002
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Correlation patterns during this period formed brain region
specific clusters (2, 6 and 9 for WM, 5 and 7 for GM). After 6 days,
metabolite concentrations correlated with either GM injury
(cluster 4) or WM injury (clusters 2,3,6 and 8), or were common
to both (cluster 1). Dependent associations could also be detected
within the phosphatidylcholines in this period (Figure S6).
Discussion
Prenatal infection and inflammation are risk factors for preterm
birth and increased neonatal morbidity. The role of prenatal
inflammation on fetal metabolism and the correlations of fetal
metabolism with brain injury are unknown. In this first analysis of
a large number of metabolites measured in fetal plasma obtained
in utero, we established that a single exposure to LPS, a component
of gram-negative bacteria, causes long-term metabolic down-
regulation and time-specific modulation of endogenous metabolic
intermediates correlating with cerebral histopathology in both grey
matter and white matter structures.
To ensure that observed changes closely reflect fetal metabolism
rather than a maternal response to LPS and/or placenta transfer
mechanisms, our model involves direct injection of LPS into a fetal
vein and at a much lower dose (some 50 to 500 fold less) than
previously reported [16–18]. Exposure to this higher and repetitive
dosage of LPS resulted in a reduction of placentome in the cross-
sectional area and contained areas of injury that could be
attributed to placental hypoperfusion and tissue hypoxia. The
higher dosing regime was also associated with cardiovascular
compromise of the fetus as indicated by acidemia, hypotension
and tachycardia [17,19]. Direct injection of a low dose of LPS into
the umbilical fetal vein minimizes the risks of an induced maternal
response. However placental effects (and subsequent maternal
responses to them) cannot be completely excluded, and neither
can any modification of placental metabolite transfer capabilities
[20,21]. Contrary to the transport of respiratory gases that diffuse
freely through the placental membranes and whose rate is mainly
dependent on concentration gradients and both uterine and
umbilical blood flow rates, the transport of nutrients and small
molecules is complex [22] and is unlikely to be explained solely by
simplistic mechanisms such as passive diffusion [23]. To our
knowledge, examples of such processes, particularly for the
metabolites discussed here, are scarce. It has been reported that
approximately 75% of glucose taken up by the ewe placenta is not
transported further to the fetus [24,25]. Recently, in vitro studies
demonstrated the placental release of kynurenine into the fetal
circulation after LPS exposure, yet at a much higher dose [26].
Altogether, and with the absence of cardiovascular compromise in
the fetus [7], the lack of evidence of maternal effects and the fact
that arterial blood samples were collected in utero, observed
metabolite changes are most likely to be indicative of fetal
metabolism perturbations [22]. The known functions of some of
these metabolites are further discussed here in relation to their
potential cause-effect mechanisms.
Acute LPS effects
LPS exposure was associated with a significant and pronounced
change in plasma metabolite levels within hours of administration.
The most notable findings are summarized in Table 2. There was
an alteration of energy metabolites associated with an acute and
transient decrease in arterial oxygen content, with an increase of a-
ketoglutarate, an intermediate of the Krebs cycle, alanine,
pyruvate, oxaloacetate and lactate, that rapidly resolved to
baseline values within 48 hours. Although LPS caused an acute,
but transient, decrease in arterial oxygen content, there were no
significant changes in heart rate or mean arterial pressure at any
time, suggesting that cardiovascular changes were unlikely the
major cause of these metabolite changes. This is in accordance
with data in septic patients showing an increase in cellular oxygen
demand due to LPS treatment, rather than hypoxia due to
hypoperfusion [27]. A possible explanation for elevated lactate
levels is the increased production of pyruvate as a result of altered
pyruvate dehydrogenase (PDH) activity, as described in skeletal
muscle tissue during chronic sepsis in rats. Because the inactivation
of PDH limits the flux of the substrate through the Krebs cycle,
excess pyruvate accumulates in cells and leads to increased
production of lactate [28]. Therefore, hyperlactataemia in sepsis is
not necessarily evidence of impaired oxygen delivery, but rather
reflects the combined effects of pyruvate dehydrogenase inhibition
and accelerated glucose transport into cells [28]. Acute changes in
mitochondrial respiration (within six hours) have also been
Figure 3. Metabolites altered by LPS after the acute phase. Fold changes (log basis 2) for the metabolites altered at FDRv0.1 at any time
point after 4 days. Abbreviations: ADMA/SDMA, Asymmetric/symmetric dimethylarginine; Total DMA, sum of ADMA and SDMA; DHA, Docosahexaenoic
acid. Significance: +=qv0.2, *=qv0.05, **=qv0.001.
doi:10.1371/journal.pone.0029503.g003
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hypothesized to result from nitric oxide and free radical formation
due to the inflammatory response [29]. Overall, these data support
that inflammation triggers mitochondrial dysregulation in the
acute phase of LPS-induced inflammatory response.
These acute alterations in Krebs cycle intermediates were
followed by acute phase elevation of sphingomyelins, kynurenine,
3-hydroxykynurenine and putrescine. These metabolites are
known to be response markers and mediators of inflammation.
The increase in sphingomyelins may reflect sphingomyelinase
activity. In fact, sphingomyelinase activity is elevated in septic
patients and subjects with organ failure due to activation of the
circulating acidic isoform. In animal experiments, increased
sphingomyelinase activity is associated with increased apoptosis
of liver cells, which can be significantly reduced along with
mortality by treatment with sphingomyelinase inhibitors [30]. The
pattern of acute phase elevation of inflammatory markers may be
explained by the well-established role of mitochondrial reactive
oxygen species (ROS) formation in driving pro-inflammatory
cytokine production. For example, ROS generated by mitochon-
drial respiration are important for normal lipopolysaccharide-
driven production of several pro-inflammatory cytokines, while
pharmacological blockade of mitochondrial ROS efficiently
reduces inflammatory cytokine production after LPS stimulation
in healthy controls [31].
We also found acute elevation of two members of the
kynurenine pathway, kynurenine and 3-hydroxyky-nurenine. This
pathway is an important regulator in both innate and adaptive
Figure 4. Correlation between metabolites and brain damage. Heatmap depicting metabolite association with white matter and grey matter
volumes during the acute phase (6–48 h) and late phase (6–9 days). Color coding follows the key (top right): blue (resp. red) correspond to positive
(resp. negative) correlation with the white and gray matter volume (red: increase in metabolite concentration correlates with maldevelopment, blue:
decrease in metabolite concentration correlates with maldevelopment, the darker the stronger the correlation). Light grey corresponds to
metabolites that were not found to be significant at FDRv0.1.
doi:10.1371/journal.pone.0029503.g004
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been suggested to be indicative of immune dysregulation. The
kynurenine pathway also has a significant impact on neuronal
activity [33]. For example, quinolinic acid can activate a
subpopulation of neuronal glutamate receptors specifically sensi-
tive to N-methyl-D-aspartate (NMDA), resulting in neuronal
depolarization and excitotoxicity [34–36]. 3-hydroxykynurenine,
which is redox active, can also cause neuronal damage via the
generation of reactive oxygen species [37].
Oxysterols are hydroxylated derivatives of cholesterol that play
important functions in lipid metabolism [38], and have been
implicated as biomarkers of acute brain damage. In particular, 24-
hydroxycholesterol (24OHC) can cross the blood-brain barrier
[39], and has been proposed as a biomarker of brain cholesterol
balance and as a marker of CNS neuronal mass [40–42]. Altered
plasma 24OHC has been observed in Alzheimer’s disease and
Multiple Sclerosis [43,44]. In addition, 24OHC and 25-hydro-
xycholesterol (25OHC) play an important role in inflammation
and inducing oligodendroglial cell death [45]. 24OHC induces the
expression of inflammatory genes such as cyclooxygenase-2
and phospholipase A2 in neural cells [46]. 25OHC, which is
synthesized from cholesterol by a specific hydroxylase [47], acts as
a potent inhibitor of cholesterol biosynthesis in different cell types.
In addition, 25OHC can alter oligodendrocyte morphology and
trigger oligodendrocyte apoptosis [45]. Therefore, the increase of
24OHC and 25OHC in the LPS-exposed animals in the acute
phase reflects disturbance in cholesterol metabolism and might
indicate the onset of neurological injury.
LPS exposure also altered plasma levels of asymmetric dimethyl
arginine (ADMA), an endogenous inhibitor of nitric oxide synthase
and also associated metabolites of symmetric dimethyl arginine
(SDMA). ADMA is elevated in patients with chronic vascular
disease, causing increased cardiovascular risk and endothelial
dysfunction [48] and are considered potential biomarkers of stroke
[49]. The role of ADMA in acute inflammatory states, however, is
less well defined, particularly in the fetus and preterm neonate. We
found that intrauterine LPS exposure caused a marked and
transient decrease in ADMA plasma concentrations during the
acute phase, as observed in endotoxaemic rats [50] and in post-
operative patients with sepsis without shock [51]. In adult animal
Table 2. Roles and functions of a selection of altered metabolites.
Acute phase
Metabolite/parameter Regulation Known functions and roles Relation to LPS exposure
pO2 Down Increased demand in O2 in the early stage of sepsis [27] Increased demand in O2
Lactate, a-ketoglutarate
pyruvate, oxalo-acetate
Up Alteration of energy metabolites in sepsis and inflammation,
role of mitochondria in the inflammatory response [29,31]
Increased mitochondrial activity and
dysfunction
3-hydroxykynurenine Down Production of neuronal damage via the generation of
reactive oxygen species [37]
Increased oxidative stress potentially
contributing to brain injury
Kynurenine Up Regulator in the innate and adaptive immune response [32]
Known excitotoxins in the kynurenine pathway [34–36]
Expression of immune response
potentially contributing to brain injury
Spermidine, putrescine Up Cell growth, proliferation, regeneration and differentiation,
regulatory mechanisms of apoptosis [63–65]
Blood-brain barrier dysfunction in ischemic events [66,67]
HI increases ODC and activates SAT1 [68–70]
Modification of polyamine levels may be neuroprotective [71]
Increased ornithine decarboxylase (ODC)
and SAT1 activities contributing to
neuronal injury
25-hydroxycholesterol Up Inhibitor of cholesterol biosynthesis, oligodendrocyte cell line
morphology and triggered apoptosis [45,47]
Alterated cholesterol biosynthesis,
contributing to oligodendroglial cell
death
24-hydroxycholesterol Up Crosses blood-brain barrier [39]
Marker of brain cholesterol balance, CNS neuronal mass,
Alzheimer’s disease and multiple sclerosis [40–44]
Induces inflammatory genes (COX-2, PLA2) in neural cells [45,46]




Down Endogenous inhibitor of nitric oxide synthase [50]
Decreased in the acute phase of sepsis [51]









Increased demand in O2 in sepsis [29]
Metabolic down-regulation after inflammation and HI,
LPS-induced reduction in mitochondrial biogenesis [52,53]
LPS-induced hibernation in the fetus
as protective adaption to harsh
environmental conditions.
Potential impact on cortical
development
3-hydroxykynurenine Up Production of neuronal damage via the generation of
reactive oxygen species [37]
Ongoing inflammatory response
Potential contributor to brain injury




Up Increased in chronic vascular disease, augments cardiovascular
risk and endothelial dysfunction, biomarker for stroke [48,49]
Endothelial dysfunction, potential
alteration in blood flow
For each metabolite, known roles and functions are summarized in relation to LPS exposure in the acute and late phases. HI: Hypoxia-ischemia, SAT1: Spermidine/
spermine N1-acetyltransferase 1.
doi:10.1371/journal.pone.0029503.t002
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suggested to have functional consequences for regulation of
microvascular tone [50]. However, in our study there were no
changes in mean arterial blood pressure or heart rate during the
period of low plasma ADMA levels, and the functional relevance
of reduced AMDA in the fetus remains to be elucidated as we did
not measure blood flow.
LPS exposure causes long-term metabolic down-
regulation
As well as acute effects, LPS exposure had an impact on long-
term fetal metabolism. The key results are summarized in Table 2.
During this phase, pO2 was significantly increased in the LPS
group compared to controls, which was associated with signifi-
cantly decreased concentrations of lactate (in blood gas analyses
and metabolomics), a-ketoglutarate, and pyruvate/oxaloacetate,
and an increase in hexose. These data (hyperglycemia, high pO2,
low lactate, a-ketoglutarate and pyruvate/oxaloacetate) show that
one single LPS exposure alters the bioenergetic status of the fetus
towards a hypometabolic condition. This condition has been
termed hibernation or metabolic down-regulation in adult septic
patients [29]. Hibernation is a suspended animation-like state of
reduced metabolic rate and reduced core body temperature. For
many animals, this hypometabolic state is a protective adaption to
harsh environmental conditions and is a regulated seasonal
response. Hibernation has also been described at the cellular level
in response to low oxygen tension, ischemic insults and sepsis. In
rodent models of sepsis the rate of oxygen consumption by certain
tissues was impaired when animals were injected with LPS, and
the fall in the rate of oxygen consumption was not due to a change
in oxygen delivery (e.g. on the basis of diminished microvascular
perfusion), but rather to an acquired intrinsic defect in cellular
respiration. A number of different biochemical mechanisms have
been postulated including reversible inhibition of cytochrome a,a3
by nitric oxide, irreversible inhibition of one or more mitochon-
drial respiratory complexes by peroxynitrite [52] and more
recently, reduction in mitochondrial biogenesis [53]. Hibernating
cells maintain viability by down-regulating oxygen consumption,
ceasing cellular function and reducing ATP demand [54]. The
metabolic down-regulation in fetuses in our study persisted ten
days after LPS exposure, which is more prolonged than the
recovery and increased mitochondrial biogenesis reported within
24 hours after LPS exposure in animal models [53]. To the best of
our knowledge this is the first time that inflammatory-induced
hibernation in the fetus has been described. Future studies are
required to examine how long this metabolic down regulation
persists.
Our findings have central implications for the treatment of
preterm infants previously exposed to intrauterine inflammation.
For example, glucose intolerance and postnatal growth retardation
are commonly seen in low-gestation newborns, which were often
exposed to intrauterine inflammation [3]. Our data might partially
elucidate this phenomenon. Secondly, determination of the
optimum oxygenation protocols in preterm remains an open
question. In cases of metabolic down-regulation the offered oxygen
would unlikely be used and might result in an increase in oxidative
stress. Current clinical treatment practice and clinical trials assume
preterm infants of a given gestational age as one metabolic
phenotype/identity. However our data indicate that within a
cohort of premature infants, there might be major differences in
the metabolic status and availability to use substrates provided,
requiring individualized therapy to provide appropriate patient
care and treatment.
Correlation of plasma metabolite levels with brain injury
We previously reported that LPS exposure in this cohort of
animals causes maldevelopment of the cortical grey and white
matter. In this study, we detected a biphasic pattern of acute and
delayed changes in correlating metabolites common to both WM
and GM injury, while several groups of metabolites were
associated to a specific brain region. Although correlation does
not necessarily entail causality, our findings have three implica-
tions. First, since the different phases of inflammation could be
discriminated, this time-dependent pattern after intrauterine
inflammation may enable determination of the current phase of
inflammation in an individual preterm infant. These results
provide insights into mechanisms and the identification of
potential therapeutic targets. Although our analysis was only
performed in plasma, the known CNS functions of some of these
metabolites indicate cause-effect relationships. For example, novel
therapeutic strategies might include inhibition of sphingomyelin-
ases, use of kynurenic acid, an antagonist at several subtypes of
glutamate receptors [55–57], to counteract the toxicity of
quinolinic acid. One limitation of our study in this respect is that
we did not measure endogenous levels kynurenic acid, which we
previously showed to be neuroprotective in neonatal hypoxic-
ischemic brain injury [57]. The modification of oxysterol signaling
might be another potential target, since white matter injury in
particular, was strongly associated with 24OHC and 25OHC,
which can activate pro-apoptotic pathways. Finally, these
metabolites might serve as potential biomarkers of developmental
brain injury and of treatment effects. Our experiment was not
primarily designed for these outcomes, as it would have required
tighter control of the false positive discovery rate, a larger animal
experiment with pre-defined endpoints, and a verification phase
on a human cohort. Nevertheless, we have demonstrated the use
of endogenous biochemical intermediates as potential biomarkers,
and their relative species-independence suggests appropriate
candidates for detecting and monitoring developmental brain
injury in a translational scenario.
Materials and Methods
Ethics Statement
The experimentation was approved by the Animal Ethical
Committee of Gothenburg, Sweden (#307-2006) and conformed
to international guidelines on the ethical use of animals. All efforts
were made to minimize the number of animals used and their
suffering.
Experimental Protocol
Sheep fetuses were randomly assigned to receive an i.v. bolus
infusion of either saline vehicle (Control group; n=7) or
Escherichia coli LPS (055:B4; Sigma-Aldrich, St. Louis, MO;
LPS group; n=9) at 102.5 + 0.5 days of gestation (term=147
days). The LPS dose was 200 ng/kg Escherichia coli based on a
fetal weight of 1 kg at the time of administration. In the first
animal models of exposure of the fetus to LPS [18,19], it was
shown that repeated (3–5 times) intravenous injections of high
doses of LPS (1 mg=kg) into a fetal vein not only induced hypoxia,
acidemia and hypotension of the fetal sheep but also impaired
placental function. In our study, the dosage of LPS was lowered to
200 ng/kg in order to mimic subtle chorioamnionitis and to
induce brain damage without compromising the fetal cardiovas-
cular system [7]. The fetal sheep were catheterized at 97–99 days
of gestation under general anaesthesia (1.5% isoflurane in pO2)
using sterile techniques. Polyvinyl catheters were placed in both
axillary arteries and one axillary vein. The fetal scalp overlying the
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drilled through the skull (5 and 15 mm anterior of bregma and
0.5 mm lateral of midline). After surgery ewes were housed in
individual cages with free access to food and water. Animals were
allowed to recover from surgery for at least three days before
experimentation, during which time i.v. antibiotics (5 mg/kg
gentamycin) were administered to the ewe once daily.
Tissue and plasma collection
Fetal blood samples were collected for blood gas and
metabolomic analyses pre-dose at baseline (BL) and post-dose at
2 hours (2 h), 6 hours (6 h) and every day up to 10 days (1–10 d)
after LPS/saline injection. At 10 d post-LPS the ewe and fetus
were sacrificed by an i.v. overdose of sodium pentobarbitone. Fetal
brains were perfusion-fixed in situ with 0.9% NaCl solution then
4% paraformaldehyde in 0.1 M phosphate buffer (Histofix,
Histolab, Gothenburg).
Histology and quantitative analysis of cortical grey and
white matter volume
For each animal a series of evenly spaced paraffin embedded
coronal sections (10 mm, section interval=150) were collected
throughout the forebrain. Between 10–12 brain levels were
collected per brain. Sections were stained with acid fuchsin/
thionin (AF/T) for quantitative analysis of grey and white matter
volume as previously described [7]. In brief, AF/T stained sections
were examined for volume changes by light microscopy using
StereoInvestigator Software V.7 (Microbrightfield, Inc., Williston,
VT). Volumetric changes in cerebral WM (excluding CC) and
cerebral cortex were determined using the Cavalieri Principle.
Metabolomic Analyses
Sample preparation and metabolomic analyses were performed
at Biocrates Life Sciences AG, Innsbruck, Austria. Protocols are
published elsewhere [58,59]. In short, multiple reaction monitor-
ing (MRM) transitions specific to 232 endogenous metabolites
were monitored using a combination of flow injection and liquid
chromatography mass-spectrometry platforms. Quantification was
performed using structurally identical or similar labeled com-
pounds that were spiked-in during sample preparation. Samples
were randomized within batches and across analytical batches. In
addition, several sample aliquots were replicated in all batches to
assess batch-to-batch variation. Metabolites that did not meet
quality control standards and/or exhibited insufficient abundances
were excluded from subsequent interpretation. The final panel
comprised 168 unique compounds: 27 acylcarnitines, 15 sphingo-
myelins, 76 glycerophosphatidylcholines, 22 amino acids, 10
biogenic amines, four prostaglandins, 10 oxysterols and four small
organic acids. A detailed list of all metabolites considered in the
final analysis is provided in Table S1. All pre-/post-analytical
procedures were performed by co-workers blinded to the
experimental groups. All methods are validated for human plasma
following guidelines documented in the FDA Guidance for
Industry-Bioanalytical Method Validation [60].
Statistical analyses
Data analyses and representations were performed within the
statistical environment R. For metabolite measurements, all
statistical analyses were performed on pre-processed, log-basis 2
transformed data and reported as such without back-transforma-
tion. Estimation of the LPS injection and time effects were
computed by generalized least squares regression. Several
specifications of the error term were allowed to include the
longitudinal structure (i.e. order 1 autocorrelation, Gaussian and
exponential spatial correlation structures with time as a
continuous covariate) and to deal with potential time-dependent
heteroscedasticity. Model selection followed the protocol of Zuur
et al. [61]. Fixed effects under consideration were tested with
Wald tests with the levels of significance (given as p in the text)
adjusted according to Benjamini and Hochberg [62] to control
the false discovery rate (FDR). By definition, FDR gives an
estimate of proportion of wrongly rejected hypotheses among all
significant hypotheses/metabolites selected for interpretation. For
each question, distribution of the raw p-values is given in the
supplementary materials. Metabolites below the FDR threshold
stated in the text are selected for downstream reporting and post
hoc testing where p-values are adjusted according to the Holm-
Bonferroni method (expressed as q in the text). Unless stated,
95% confidence intervals for the statistic of interest are reported
and graphed. Clinical parameters at baseline and the outcome of
histology are reported as mean +/2 standard deviation, and
potential bias in the experimental design was assessed by means
of two-sample t tests. Time-dependent changes for altered
metabolites are described by the coefficients of the linear model
and further grouped by hierarchical clustering using the absolute
value of the Pearson correlation between coefficients as the
similarity metric. This allows a compact and direct visualization
of individual metabolite behavior without losing information
about the magnitude of the changes and potential anti-
correlation.
Supporting Information
Figure S1 Base deficit and pH over the course of the
experiment. Mean and 95% confidence intervals are given for
the LPS (thick line) and control (dashed line) groups. Significance
summarized as: +=qv0.2; *=qv0.05; **=qv0.001.
(TIFF)
Figure S2 Histograms of the 168 raw p values obtained by time
course modelling in the LPS-treated and sham-operated animal
cohorts. Solid line plotted at y=8.4 (=168*0.05) corresponds to
the density to be expected should all metabolites not change over
the first 3 days (null hypothesis).
(TIFF)
Figure S3 Time courses of the glycerophospholipids altered in
the LPS cohort within the first 3 days post-injection. Left:
dendrogram from the hierachical clustering (HCA) based on the
absolute value of the correlation between coefficients of the linear
model. Right: explicit display of each metabolite time course in the
clusters identified by HCA. The average time course is graphed as
a dashed line.
(TIFF)
Figure S4 Multivariate correlation between the full metabolite
profile (i.e. 168 metabolites) with the white and grey matter
volumes analysis by partial least square regression (PLS) at each
time point. Y-axis: correlation coefficient (in %) between predicted
WM/GM volumes by leave-one-out and actual WM/GM
volumes. Negative correlation coefficients are set to 0 for
visualisation purposes.
(TIFF)
Figure S5 Density histograms of the raw p values obtained for
the correlation analyses on (a) the grey and (b) the white matter
volumes at the acute (6–24 h) and late phases (6–9 d). The main
effect corresponds to the grey/white matter volume term and
interaction to the interaction term between grey/white matter
volume and time. The solid line corresponds to the density to be
Fetal Inflammation Primes Fetal Metabolism
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e29503expected should all metabolites are not correlated with the
parameter of interest during the given period (null hypothesis).
(TIFF)
Figure S6 Heatmap depicting glycerophosphatidylcholines and
their association with white matter (left) and grey matter histology
(right) over the two periods 6–48 h and 6–9 days.
(TIFF)
Table S1 Metabolite panel. List of metabolites used in the study.
(PDF)
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